| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
SNX7 targets the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. Importantly, it inhibits the CDKI pathway without directly blocking the catalytic activity of Cyclin-Dependent Kinases (CDKs). This mechanism is distinct from that of pan-CDK inhibitors, as SNX7 preserves cell cycle arrest while suppressing transcriptional activation. By targeting this pathway, SNX7 serves as a valuable tool for studying cellular senescence and various other CDKI-related diseases.
|
|---|---|
| ln Vitro |
In vitro, SNX7 has been validated for use at a screening concentration of 20 μM in studies of Senescence-Associated Secretory Phenotype (SASP) and senescence morphology. As a CDKI pathway inhibitor that does not block CDK catalytic activity, it is used to dissect the role of transcriptional regulation in senescence and other CDKI-related processes. Its unique mechanism allows researchers to study cell cycle arrest and senescence independently of direct CDK inhibition. It is soluble in DMSO at a concentration of 250 mg/mL (1049.19 mM).
|
| ln Vivo |
Specific in vivo activity data for SNX7 have not been published; it is currently intended for in vitro applications only. As a research tool for studying the CDKI pathway, its effects on senescence and related diseases have not been characterized in animal models. The foundational patent and subsequent literature have not disclosed quantitative in vivo efficacy data. Further research would be required to evaluate its pharmacokinetics, efficacy, and safety in vivo.
|
| Enzyme Assay |
Typical in vitro assays for SNX7 involve studying its effects on the CDKI pathway and senescence. For enzyme/receptor binding studies, assays that measure CDK catalytic activity can be used to confirm that SNX7 does not directly inhibit CDK enzymes. This distinguishes it from direct CDK inhibitors. Researchers may employ in vitro kinase activity assays using purified CDK/cyclin complexes to demonstrate the lack of direct catalytic inhibition, thereby validating its unique mechanism of action.
|
| Cell Assay |
Cellular assays for SNX7 typically involve treating cultured cells, such as fibroblasts or other senescence models, with the compound. A validated screening concentration of 20 μM is used to study the Senescence-Associated Secretory Phenotype (SASP) and senescence morphology. Following treatment, researchers can assess markers of senescence, such as SA-β-galactosidase activity, cell cycle analysis by flow cytometry, and expression of SASP-related genes (e.g., IL-6, IL-8) by qPCR or ELISA.
|
| Animal Protocol |
In vivo animal experiments for SNX7 have not been reported in the available literature. As a research tool primarily used for in vitro applications, no specific in vivo protocols have been established. For potential in vivo studies, typical animal models for senescence or cancer research could be employed. However, no such studies have been published, and the compound is currently only available for research use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for SNX7 have not been published. As a small molecule with a molecular weight of 238.28 g/mol, it would be expected to have reasonable oral bioavailability if administered. However, no ADME (Absorption, Distribution, Metabolism, Excretion) studies have been reported. The compound is soluble in DMSO, but its formulation for in vivo use has not been described.
|
| Toxicity/Toxicokinetics |
Toxicological data for SNX7 are not available in the consulted sources. As a research compound used in vitro, comprehensive toxicological studies have not been reported. The compound is intended for research use only and is not approved for human use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
SNX7 (WAY-323879) is a small-molecule chemical probe that inhibits the CDKI pathway without blocking CDK catalytic activity. Discovered through a high-throughput screen, it belongs to the SNX2-class compound family. Its unique mechanism preserves cell cycle arrest while suppressing transcriptional activation, making it a valuable tool for studying cellular senescence and other CDKI-related diseases. It has been validated at a 20 μM screening concentration for SASP and senescence morphology studies. The compound is not approved for any clinical indication and is for research use only.
|
| Molecular Formula |
C15H14N2O
|
|---|---|
| Molecular Weight |
238.28
|
| Exact Mass |
238.11
|
| CAS # |
685097-43-2
|
| PubChem CID |
5736327
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
416.4±48.0 °C at 760 mmHg
|
| Flash Point |
205.7±29.6 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
4.58
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN1C2=CC=CC=C2N=C1/C=C/C3=CC=CO3
|
| InChi Key |
CVDSCSOYABNWQH-MDZDMXLPSA-N
|
| InChi Code |
InChI=1S/C15H14N2O/c1-2-17-14-8-4-3-7-13(14)16-15(17)10-9-12-6-5-11-18-12/h3-11H,2H2,1H3/b10-9+
|
| Chemical Name |
1-ethyl-2-[(E)-2-(furan-2-yl)ethenyl]benzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~1049.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (8.73 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1967 mL | 20.9837 mL | 41.9674 mL | |
| 5 mM | 0.8393 mL | 4.1967 mL | 8.3935 mL | |
| 10 mM | 0.4197 mL | 2.0984 mL | 4.1967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
